±Û ¼öÁ¤Çϱâ
±Û¾´ÀÌ
E-mail
Homepage
±ÛÁ¦¸ñ
±Û
My battery's about to run out
skelaxin indications
Under Tuesday's deal, Roche will pay $10 million up front, with development and commercial milestones of up to $412.5 million for exclusive access to Inovio's DNA-based vaccines INO-5150 for prostate cancer and INO-1800 for hepatitis B.
ºñ¹Ð¹øÈ£
(¼öÁ¤°ú »èÁ¦½Ã ÇÊ¿ä!! )